Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

ALNYLAM PHARMACEUTICALS

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-16 06:26:08 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 21, 2025
Income
$60,000.00
Expenses
Not reported
Filing UUID
c578ba03-818c-4b8b-8641-f171bd1bf1eb
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022

Literal federal measure citations: H.R. 1672

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.